Beyond the Risk Calculator: Can Heart Scans Redefine Preventive Cardiology?

The Evolving Landscape of Heart Disease Prevention

For decades, the standard protocol for preventing cardiovascular disease has relied on a mathematical guessing game. Doctors aggregate data points—age, blood pressure, cholesterol levels, and smoking status—into algorithms like the "pooled cohort equations" (PCE) to estimate a patient’s ten-year risk of a heart attack or stroke. If the number hits a certain threshold, the prescription pad comes out for statins.

However, this statistical approach has a glaring blind spot: it is an estimation, not a diagnosis. Many patients who suffer a sudden, life-altering cardiovascular event never triggered a "high-risk" flag on these calculators. Conversely, many others are prescribed lifelong medication based on risk scores that may overestimate their personal danger.

A landmark study, the CorCal Outcomes trial, presented at the ESC Congress 2026, has thrust this debate into the spotlight. By pitting traditional risk-assessment models against direct physiological evidence—specifically coronary artery calcium (CAC) scans—researchers have uncovered a provocative reality: we may be able to identify, treat, and engage patients more effectively by looking directly at their arteries rather than relying on a spreadsheet.


Chronology of the CorCal Outcomes Trial

The journey to the findings presented in 2026 began with a fundamental question: Is there a more precise way to identify who truly needs statins?

  1. Trial Initiation: The CorCal Outcomes trial was launched to compare the standard-of-care (PCE-based risk assessment) against a strategy guided by coronary artery calcium (CAC) imaging.
  2. Patient Recruitment: Researchers recruited 5,772 participants from the Canyons and Desert regions of Intermountain Health Care in the United States. To ensure a focus on primary prevention, all participants were free of known atherosclerotic cardiovascular disease (ASCVD) and diabetes, and none were currently taking statins.
  3. The Randomization Phase: Between 2021 and 2022, participants were randomized in a 1:1 ratio. One group followed the traditional risk-score pathway, while the other underwent a CT scan to quantify calcium buildup in the heart’s arteries.
  4. The Follow-Up: Over an average of 4.2 years, the clinical team tracked Major Adverse Cardiovascular Events (MACE), including mortality, myocardial infarction (heart attack), stroke, and arterial revascularization procedures.
  5. Data Disclosure: The final analysis was completed in 2026, revealing a complex picture of clinical outcomes, prescription frequency, and, perhaps most surprisingly, patient adherence to medical advice.

Supporting Data: A Tale of Two Strategies

The results of the CorCal trial present a fascinating paradox. When researchers compared the two groups, the clinical outcomes were remarkably similar, yet the "pathway to get there" was vastly different.

Equal Outcomes, Different Intensity

The primary goal was to see if one method prevented more heart attacks than the other. The data showed that 2.7% of participants in both groups experienced a MACE. Statistically, the two strategies appeared to offer identical protection. However, the study failed to meet the rigorous statistical bar for "noninferiority," meaning researchers cannot definitively claim the scans are as safe as the traditional method—only that they performed at an equal rate in this specific cohort.

The Efficiency Gap

The most striking data point concerned the frequency of statin recommendations. In the group relying on traditional risk scores, physicians recommended statins more than three times as often as they did in the group guided by CAC scans. This suggests that traditional calculators may lead to "over-prescribing" or, at the very least, a much wider net of intervention that does not necessarily translate into a lower rate of heart attacks compared to a more targeted approach.

The "Visual Motivation" Factor

Perhaps the most intriguing finding was the stark difference in patient compliance. Among those advised to start statins, only 23% of the traditional-risk group consistently followed their prescription. In contrast, 62% of those in the calcium-scan group adhered to their treatment. Patients who could literally "see" the calcium buildup in their arteries were nearly three times more likely to stick to their medication.


Official Responses and Expert Perspective

Dr. Joseph B. Muhlestein, Principal Investigator from the Intermountain Medical Center, emphasized that while the trial didn’t definitively "win" the debate, it provided vital insights into the patient experience.

"For far too many patients, the first symptom of ASCVD is a heart attack," Dr. Muhlestein noted during the ESC Congress. "Statins have been shown to be highly effective in the prevention of ASCVD; however, there is a major gap in risk assessment, statin initiation, and statin persistence."

Dr. Muhlestein acknowledged the limitations of the study, noting that lower-than-anticipated event rates reduced the statistical power of the trial. "The power of the study to detect a difference was reduced… we did not demonstrate noninferiority between the groups. However, the study did provide important hypothesis-generating insights into the efficiency of statin initiation and adherence."

Other cardiology experts observing the study have noted that the 62% adherence rate in the scan group is a "holy grail" in preventative medicine. Improving adherence is often more difficult than choosing the right drug; if a diagnostic test can serve as a "behavioral intervention," its value may extend far beyond its ability to detect plaque.


Implications for Clinical Practice

The CorCal Outcomes trial does not signal the immediate death of traditional risk calculators, but it does suggest that the future of cardiology is shifting toward personalized, image-based medicine.

1. Refining the "Moderate Risk" Category

For patients in the "grey zone"—those whose risk scores are borderline—the CAC scan offers a tie-breaker. The 2025 update to the ESC/EAS Guidelines for the management of dyslipidemias already supports this, recommending that clinicians utilize calcium scoring to clarify the risk profile of moderate-risk patients.

2. The Power of Patient Education

The study underscores a critical, often overlooked aspect of clinical care: the psychological impact of diagnostic data. Traditional scores are abstract, often confusing, and sometimes dismissed by patients as "just numbers." A scan showing calcified arteries is tangible. It transforms the conversation from a doctor telling a patient they are "at risk" to a patient seeing evidence of disease, which appears to be a powerful catalyst for long-term health behavior changes.

3. The Need for Future Research

The "failure" to prove noninferiority is not a defeat; it is a roadmap. Researchers now have a clearer idea of how to structure the next generation of trials. A larger, more robust study with a higher number of events is required to confirm whether the "scan-first" approach is truly superior in the long term.

4. Cost and Accessibility

While the study highlights the efficacy of the scan approach, policy makers must now weigh the cost-effectiveness. Is it cheaper to scan everyone, or to put everyone on statins? If the scan approach leads to far fewer statin prescriptions while maintaining the same level of health outcomes, the potential for reduced drug spending—and reduced side effects for patients who didn’t need the drugs in the first place—could make the scan a more economical option in the long run.

Conclusion

The CorCal Outcomes trial has successfully challenged the status quo. By highlighting the limitations of conventional risk calculators and the potential for imaging to improve both clinical efficiency and patient adherence, it has opened a new chapter in preventative cardiology. While the medical community waits for further, more powerful trials to confirm these findings, one thing is clear: the most effective way to prevent a heart attack may be to move beyond the calculator and look, quite literally, at the heart of the matter.

More From Author

From Bedside to Boardroom: How Dr. Pallav Halani’s Respiratory Roots Built a Pediatric Pulmonology Career